1-乙基-6-氟-1,4-二氢-4-氧代-7-(4-芳酰硫代氨甲酰基-1-哌嗪基)-3-喹啉羧酸的合成及抗菌作用

Thirteen new 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-aroyl-thiocarbamoyl- 1 piperazinyl)-3-quinoline carboxylic acids were prepared, Their structures were characterized by elemental analysis, IR, HNMR and MS spectra.Preliminary pharmacological tests indicated that some of compounds Ia～m possess strong inhibiting activity against Escherichia coli, Bacillus subtilis and Proteus at concentration of 100 μg/ml.     

环糊精在鼻腔给药系统中的应用

综述了环糊精作为鼻腔给药系统赋形剂的应用及安全性.     

健康志愿者口服青蒿琥酯片剂的生物利用度

本文报道用放射免疫测定法研究口服青蒿琥酯片剂的生物利用度,结果为静脉注射青蒿琥酯后的血药时程为二房室模型,T1/2β为33.96±4.73分钟;口服青蒿琥酯片剂后的血药时程为一房室模型,其达峰时间为53.07±20.58分钟,峰浓度为1.94±1.05mg/L(1.94±1.05μg/ml),T1/2k为41.35±17.89分钟,绝对生物利用度为40.39±14.99％。结果提示口服青蒿琥酯片剂后,在人体内的吸收速度较快,而吸收程度较差。     

Naphthalimido derivatives as antifolate thymidylate synthase inhibitors

A new series of N-(substituted)benzyl-1,8-naphthalimides 4, structurally related to the previously reported thymidylate synthase (TS) inhibitor naphthaleins 3, were synthesized and compounds tested for their inhibition of several species of TS. Moreover, their in vitro cytotoxicity together with antimycotic and antibacterial properties were assayed. While no activity was detected in the antibacterial tests, the m-nitro (4ae) and the p-nitro (4af) derivatives were found able to partially inhibit TS at low micromolar concentrations. Introduction of nitro or (substituted)-amino groups in position 4 of the naphthalic ring always led to less active compounds.     

抗病毒剂研究──Ⅳ．6－氨基－9－（N~4′－芳香基取代乙醛缩氨基硫脲）嘌呤衍生物的合成

合成了６个６－氨基－９－（Ｎ~４′－芳香基取代乙醛缩氨基硫脲）嘌呤衍生物，并进行了抗核型多角体病毒（ＮＰＶ）活性实验。结果显示该类化合物对ＮＰＶ的抑制活性可达６７％。     

骨质疏松防治药物研究（8）：喹啉酮类新衍生物的合成

作者合成了９个喹啉酮类新衍生物，其结构经红外光谱，核磁共振氢谱，质谱及元素分析证实，对合成的化合物ＴＭ－９进行抗骨质疏松活性测定，初步结果表明，目标化合物ＴＭ－９促进骨形成活性高于日本已上市的异丙氧基异黄酮。     

磺胺噻二嗪硫酮衍生物的合成及其抑菌活性

利用药物化学骈合原理设计并合成了一系列新的３，５－二取代１，３，５－噻二嗪－２－硫酮类化合物，其结构经红外光谱，紫外光谱及元素分析证实，抑菌活性试验显示了良好的抑菌活性。     

1-(2-羟基-3-芳氧基丙基)-4-芳酰基哌嗪的合成

根据拼合原理,设计并合成了19个1-(2-羟基-3-芳氧基丙基)-4-芳酰基哌嗪类化合物。对其中8个化合物I₁～I₈进行了药理试验,发现它们有明显的降压活性及α-受体阻滞活性。     

2,7,12,18-四甲基-13,17-二(3-羟基丙基)卟啉的合成及其光敏化活性

由氯化高铁次卟啉经脱铁、酯化、还原合成了光敏剂２，７，１２，１８－四甲基－１３，１７－二（３－羟基丙基）卟啉，并测定其光敏活性     

Guanidinium-carboxylate interactions

The crystal structures of the 1:1 complexes methylguanidinium benzylhydrogenmalonate, (C₂N₃H₈)⁺(C₁₀H₉O₄)^?, MGD.BMAL, and methylguanidinium ethylhydrogenmalonate, (C₂N₃H₈)⁺(C₅H₇O₄)^?, MGD.EMAL, and of the 2:1 complex methylguanidinium sulfate, (C₂N₃H₈)₂SO₄, have been determined from three-dimensional X-ray data. For MGD.BMAL, the complex crystallizes in the triclinic space group P with two formula units in a cell of dimensions a = 6.277(5), b = 8.470(3), c = 13.191(6)Å, α= 91.01(1), β= 99.64(9), γ= 90.83(5)°. The structure has been refined to a final value of R = 0.061 based on 1511 intensities. The MGD.EMAL complex is also triclinic, space group P with two molecules in a cell of dimensions a = 9.254(7), b = 9.625(6), c = 6.778(2) Å, α= 109.6(1), β= 100.8(1), γ= 62.7(1)Å. The crystals of this compound are of low quality, and the final value is R = 0.109 based on 706 intensities. (MGD)₂SO₄ is orthorhombic, space group P2₁2₁2₁, with four molecules in a cell of dimensions a = 7.100(4), b = 12.151(3), c = 13.108(2) Å. Refinement has converged to R = 0.054 based on 907 data. All three crystals exhibit extensive interionic hydrogen bonding. The hydrogen bonding in MGD.BMAL includes a Type B interaction and a Type 1 interaction, the latter being a pairwise interaction from both amino nitrogen atoms on the cation to two carboxylate oxygen atoms from the two different carboxylate groups in an anion. In MGD.EMAL, the anion participates in both a Type A and a Type B pairwise interaction with two neighboring cations. The possible implications of the hydrogen bonding patterns in these two compounds for the role of arginyl side chains in protection of γ-carboxyglutamate residues from decarboxylation are discussed.